Australian Red Cross Blood Service

We include a list of interesting reading in each iTransfuse Express. The links are all kept here. Some will be accessible by subscription, but many are free access.

Transfusion practice

Red Cells

Judd WJ. Editorial - When Should Tests for Unexpected Antibodies Be Done During Pregnancy? Transfusion 2011; 51(7): 1366–1368.

Dajak S et al. Severe Hemolytic Disease of Fetus and Newborn Caused by Red Blood Cell Antibodies Undetected at First-Trimester Screening. Transfusion 2011; 51(7): 1380–1388.

Shander A et al. Appropriateness of Allogeneic Red Blood Cell Transfusion: The International Consensus Conference on Transfusion Outcomes. Transfusion Medicine Reviews 2011; 25(3): 232-246.

Platelets

Apelseth TO et al. Current practice and future directions for optimization of platelet transfusions in patients with severe therapy-induced cytopenia. Blood Reviews 2011; 25(3): 113–122.

Shaz BH & Hillyer CD. Residual risk of D alloimmunization: is it time to feel safe about platelets from D+ donors? Transfusion 2011; 51(6): 1132–1135.

Cid J et al. Platelet transfusions from D+ donors to D− patients: a 10-year follow-up study of 1014 patients. Transfusion 2011; 51(6): 1163–1169.

Perseghin P. High concentration plasma-reduced plateletapheresis concentrates. Transfusion and Apheresis Science 2011; 44(3): 273-276.

Refaai MA et al. An association of ABO non-identical platelet and cryoprecipitate transfusions with altered red cell transfusion needs in surgical patients. Vox Sanguinis 2011; 101(1): 55–60.

Fuller AK et al. A Comprehensive Program to Minimize Platelet Outdating. Transfusion 2011; 51(7): 1469–1476.

Plasma

Borgman MA et al. The effect of FFP:RBC ratio on morbidity and mortality in trauma patients based on transfusion prediction score. Vox Sanguinis 2011; 101(1): 44–54.

Tinmouth AT & McIntyre L. The conundrum of persistent inappropriate use of frozen plasma.
Critical Care 2011; 15: 160.

Stanworth SJ et al, the Intensive Care Study of Coagulopathy (ISOC) investigators. A national study of plasma use in critical care: clinical indications, dose and effect on prothrombin time.
Critical Care 2011; 15: R108

Levi M. Prevention and Treatment of Coagulopathy in Patients Receiving Massive Transfusions. Vox Sanguinis 2011; 101(2): 154–174.

Curry N et al. Trauma-Induced Coagulopathy—A Review of the Systematic Reviews: Is There Sufficient Evidence to Guide Clinical Transfusion Practice? Transfusion Medicine Reviews 2011; 25(3): 217-231. 

General transfusion practice

Padmakumar AD & Bellamy MC. Review of current practice of blood and component transfusion: critical issues for the critically ill patient. JICS 2011; 12(2): 134-139.

Roseff SD. Neonatal transfusion practice: should our policies mature with our patients?
Transfusion 2011; 51(5): 908-913.

Court EL et al. Informed consent and patient understanding of blood transfusion. Transfusion Medicine 2011; 21(3): 183-189.

Brown CJ & Navarrete CV. Clinical Relevance of the HLA System in Blood Transfusion. Vox Sanguinis 2011; 101(2): 93–105.

Back to top

Transfusion Safety

Wilson K. A Framework for Applying the Precautionary Principle to Transfusion Safety. Transfusion Medicine Reviews 2011; 25(3): 177-183.

Vamvakas EC. Letter to the Editor - Purported deleterious effects of “old” versus “fresh” red blood cells: an updated meta-analysis. Transfusion 2011; 51(5): 1122-1123.

Pettilä V et al, the Blood Observational Study Investigators for the ANZICS Clinical Trials Group. Age of red blood cells and mortality in the critically ill. Critical Care 2011; 15: R116.

Lacroix J et al. The Age of Blood Evaluation (ABLE) Randomized Controlled Trial: Study Design. Transfusion Medicine Reviews 2011; 25(3): 197-205.

Napolitano LM. Blood transfusion and the lung: first do no harm? Critical Care 2011; 15:152.

King KE & Ness PM. How do we prevent transfusion-associated graft-versus-host disease in children? Transfusion 2011; 51(5): 916-920.

Vraets A et al. Transfusion-Associated Hyperkalemia. Transfusion Medicine Reviews 2011; 25(3): 184-196.

Mintz PD. Editorial - Cesium cessation? An Advantage of Pathogen Reduction Treatments. Transfusion 2011; 51(7): 1369–1376.

Fast LD et al. Inactivation of Human White Blood Cells in Platelet Products after Pathogen Reduction Technology Treatment in Comparison to Gamma Irradiation. Transfusion 2011; 51(7): 1397–1404.

Back to top